Recombinant porcine factor VIII use in bleed treatment in non-severe haemophilia A inhibitor patients: Dosing strategies and efficacy

被引：0
|
作者：
Ellsworth, Patrick [1 ,2 ]
Chen, Sheh-Li [3 ]
Key, Nigel [1 ]
Abajas, Yasmina [2 ]
Ma, Alice [1 ]
机构：
[1] Univ N Carolina, Dept Med, Div Hematol Oncol, Houpt Bldg,CB 7305,170 Manning Dr,3rd Floor, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Dept Pediat, Div Pediat Hematol Oncol, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27599 USA
来源：
HAEMOPHILIA | 2021年 / 27卷 / 01期
关键词：
OBI-1; SEQUENCE; SAFETY;
D O I：
10.1111/hae.14111
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E147 / E150
页数：4
相关论文
共 50 条
  • [11] Use of recombinant porcine factor VIII in treatment of acquired hemophilia A in four patients
    Kaveney, A.
    Danish, M.
    Philipp, C.
    HAEMOPHILIA, 2019, 25 : 34 - 35
  • [12] The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A
    Lusher, JM
    Lee, CA
    Kessler, CM
    Bedrosian, CL
    HAEMOPHILIA, 2003, 9 (01) : 38 - 49
  • [13] A transient high titer inhibitor in a boy with severe haemophilia A treated with recombinant factor VIII
    Gottstein, S.
    Budde, U.
    Klamroth, R.
    HAMOSTASEOLOGIE, 2009, 29 : S61 - S61
  • [14] Use of porcine factor VIII in inhibitor patients: revisited
    Hoots, W. K.
    HAEMOPHILIA, 2009, 15 (02) : 624 - 624
  • [15] Manufacturing Process Of A Recombinant Porcine Sequence Factor VIII For The Treatment Of Haemophilia A In The Presence Of Inhibitors
    Lai, C. K.
    Xiong, Y.
    Deer, F.
    Wojciechowski, P.
    HAEMOPHILIA, 2015, 21 : 64 - 64
  • [16] Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non-severe haemophilia A
    Rejto, Judit
    Koenigsbruegge, Oliver
    Grilz, Ella
    Hofer, Stefanie
    Mauracher, Lisa-Marie
    Gabler, Cornelia
    Schuster, Gerhard
    Feistritzer, Clemens
    Sunder-Plassmann, Raute
    Quehenberger, Peter
    Gebhart, Johanna
    Ay, Cihan
    Pabinger, Ingrid
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (05) : 1081 - 1086
  • [17] Measurement of recombinant porcine factor VIII in patients with congenital haemophilia A and inhibitors in the presence of emicizumab
    Pfrepper, Christian
    Klamroth, Robert
    Ettingshausen, Carmen Escuriola
    Petros, Sirak
    Siegemund, Annelie
    Siegemund, Thomas
    HAEMOPHILIA, 2024, 30 (02) : 545 - 553
  • [18] Peri-operative desmopressin combined with pharmacokinetic-guided factor VIII concentrate in non-severe haemophilia A patients
    Romano, Lorenzo G. R.
    Schutte, Lisette M.
    van Hest, Reinier M.
    Meijer, Karina
    Laros-van Gorkom, Britta A. P.
    Nieuwenhuizen, Laurens
    Eikenboom, Jeroen
    Heubel-Moenen, Floor C. J. I.
    Uitslager, Nanda
    Coppens, Michiel
    Fijnvandraat, Karin
    Driessens, Mariette H. E.
    Polinder, Suzanne
    Cnossen, Marjon H.
    Leebeek, Frank W. G.
    Mathot, Ron A. A.
    Kruip, Marieke J. H. A.
    HAEMOPHILIA, 2024, 30 (02) : 355 - 366
  • [19] The in vitro procoagulant effect of recombinant porcine factor VIII in patients with inherited haemophilia A and inhibitors
    Dargaud, Yesim
    Nougier, Christophe
    Desage, Stephanie
    Meunier, Sandrine
    Lienhart, Anne
    HAEMOPHILIA, 2022, 28 : 40 - 41
  • [20] Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A
    Spira, Jack
    Plyushch, Olga R.
    Andreeva, Tatyana A.
    Khametova, Rosa N.
    THROMBOSIS AND HAEMOSTASIS, 2008, 100 (03) : 429 - 434
12345